Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 9Melanoma 4Neoplasms 3Multiple Myeloma 3Skin Neoplasms 2Polycystic Ovary Syndrome 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Resectable Pancreatic Ductal Adenocarcinoma 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Obesity 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Meningioma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Inflammation 1

Interventions

Cyclophosphamide 10ofatumumab 8fludarabine 6Rituximab 5fludarabine phosphate 4Bendamustine Hydrochloride 4venetoclax 3obinutuzumab 3ibrutinib 3acalabrutinib 3Melphalan 3pirtobrutinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lenalidomide 2Immunotherapy, Adoptive 2Busulfan 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, B-Cell × Tablets × Clear all
NCT01563055 2015-08-10

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

GlaxoSmithKline

Phase 2 Completed
10 enrolled 52 charts
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡